Table 2.
Compound | R1 | R2 | Recovery of ΔΨm (%) | ATP Recovery (%) | MTT |
ROS Inhibition (%) | |
---|---|---|---|---|---|---|---|
Recovery (%) | Viability (%) | ||||||
7 (VH034) | 78% | 42% | 28% | 95% | 97% | ||
9 (VH057) | OMe | Me | 30% | ND | ND | ND | ND |
10 (VH058) | OEt | Me | 52% | 49% | 45% | 87% | −177% |
11 (VH059) | OEt | i-Bu | 59% | ND | ND | ND | −234% |
12 (VH060) | OEt | n-Bu | 1% | ND | ND | ND | ND |
13 (VH061) | OMe | 66% | 14% | ND | ND | ND | |
14 (VH062) | OMe | 77% | 122% | 92% | 120% | 136% | |
15 (VH063) | OEt | 86% | 31% | 59% | 139% | −4% | |
16 (VH064) | OMe | 74% | 38% | 32% | 135% | 112% | |
17 (VH065) | 72% | −105% | ND | ND | ND | ||
18 (VH066) | 53% | −18% | ND | ND | ND | ||
19 (VH067) | 73% | −77% | ND | ND | ND | ||
20 (VH068) | 50% | −55% | ND | ND | ND | ||
Piracetam | 60% | 127% | 29% | 132% | 129% | ||
CsA | 55% | −46% | 61% | 90% | NDa |
ND: Not determined.